ClinicalTrials.Veeva

Menu

Nellcor™ Abbreviated Sensor Additional Data Collection

Medtronic logo

Medtronic

Status

Active, not recruiting

Conditions

Oxygen Saturation Measurement

Study type

Observational

Funder types

Industry

Identifiers

NCT07201961
MDT25017NQABAD

Details and patient eligibility

About

To collect data on a variety of market approved Nellcor™ pulse oximetry sensors with the Nellcor™ Pulse Oximetry device to support the market approval.

Full description

The purpose of this study is to collect data on the Nellcor™ Pulse Oximetry device when paired with a variety of Nellcor™ Market Released sensors under invasive, controlled desaturation conditions, to verify Pulse Rate and SpO2 accuracy in a diverse participant population over a specified saturation range.

Enrollment

55 estimated patients

Sex

All

Ages

18 to 51 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Male or female participants ≥ 18 years of age, and < 51 years of age.
  2. Participant is willing and able to comply with study procedures and duration.
  3. Participant is willing to sign an ICF.
  4. Participant weighs > 40kg (88.2 lb).
  5. Participant is a non-smoker or has not smoked within 36 hours prior to the study.
  6. Cleared same day health assessment form and health screening
  7. Successful perfusion index ulnar/ulnar+radial ratio test (Assessed via the Allen's Test) showing adequate collateral blood flow.

Exclusion criteria

  1. Participant is considered as being morbidly obese (defined as BMI >39.5).

  2. Compromised circulation, injury, or physical malformation of fingers, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized)

  3. Participants of childbearing potential who are pregnant, who are trying to get pregnant, or who have a urine test positive for pregnancy on the day of the study.

  4. Subjects with COHb levels >3% as assessed by CO-Oximetry during the procedure

  5. tHb < 10 g/dl as assessed by CO-Oximetry during the procedure

  6. MetHb ≥ 2% as assessed by CO-Oximetry during the procedure

  7. Participants with known respiratory conditions such as:

    1. uncontrolled / severe asthma
    2. flu or influenza type infection
    3. pneumonia / bronchitis
    4. shortness of breath / respiratory distress
    5. unresolved respiratory or lung surgery
    6. emphysema, COPD, lung disease
    7. recent COVID (last 2 months)
  8. Participants with known heart or cardiovascular conditions such as:

    1. Uncontrolled hypertension (systolic pressure >140mmHg, or diastolic pressure >90mmHg on 3 consecutive readings day of screening)
    2. previous cardiovascular surgery
    3. chest pain (angina)
    4. heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)
    5. previous heart attack
    6. blocked artery
    7. unexplained shortness of breath
    8. congestive heart failure (CHF)
    9. history of stroke and/or transient ischemic attack
    10. carotid artery disease
    11. myocardial ischemia
    12. myocardial infarction
    13. cardiomyopathy
    14. implantable active medical device such as pacemaker or automatic defibrillator
  9. Self-reported health conditions as identified in the Health Assessment Form:

    1. Diabetes
    2. uncontrolled thyroid disease
    3. kidney disease / chronic renal impairment
    4. history of seizures (except childhood febrile seizures)
    5. epilepsy
    6. history of unexplained syncope
    7. recent history of frequent migraine headaches (within the last 2 months)
    8. recent symptomatic head injury (within the last 2 months)
    9. cancer requiring chemotherapy, radiation, or current treatment
    10. participants with known clotting disorders
    11. history of bleeding disorders or personal history of prolonged bleeding from injury
    12. history of blood clots
    13. hemophilia
    14. sickle cell trait or disease
    15. current use of blood thinner: prescription or daily use of aspirin
    16. participants with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors
    17. participants with severe allergy to iodine (only applicable if iodine is used)
    18. participants with prior or known severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocain) or heparin
    19. arterial cannulation within the last 30 days prior to study date, (this may exclude only one radial artery site, left or right)
    20. history of clinically significant complications from previous arterial cannulation
    21. unwillingness or inability to remove colored nail polish or colored artificial nails other than clear from test digits
    22. other known health condition, upon disclosure in Health Assessment form
  10. Failure of the Allen's Test.

Trial design

55 participants in 1 patient group

Healthy Volunteers
Description:
All subjects who meet the inclusion criteria and none of the exclusion criteria will be enrolled into the test group and will participate in data collection with use of the Nellcor™ Pulse Oximetry device with each of the market-released Nellcor™ Pulse Oximetry test sensors.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems